Faisal Khurshid
Stock Analyst at Jefferies
(4.74)
# 281
Out of 5,182 analysts
43
Total ratings
62.5%
Success rate
54.38%
Average return
Main Sectors:
Stocks Rated by Faisal Khurshid
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals | Assumes: Buy | $48 → $40 | $21.00 | +90.48% | 1 | Mar 30, 2026 | |
| FDMT 4D Molecular Therapeutics | Assumes: Buy | $40 → $21 | $9.45 | +122.22% | 1 | Mar 30, 2026 | |
| PTCT PTC Therapeutics | Downgrades: Hold | $91 → $76 | $69.22 | +9.79% | 1 | Mar 30, 2026 | |
| VSTM Verastem | Assumes: Buy | $19 → $15 | $5.54 | +170.76% | 1 | Mar 30, 2026 | |
| PTGX Protagonist Therapeutics | Maintains: Outperform | $107 → $110 | $98.51 | +11.66% | 2 | Mar 19, 2026 | |
| KYMR Kymera Therapeutics | Assumes: Buy | $122 → $110 | $86.68 | +26.90% | 4 | Mar 16, 2026 | |
| INSM Insmed | Assumes: Buy | $228 | $135.98 | +67.67% | 1 | Mar 16, 2026 | |
| COGT Cogent Biosciences | Assumes: Buy | $55 | $36.61 | +50.25% | 1 | Mar 16, 2026 | |
| DSGN Design Therapeutics | Initiates: Buy | $15 | $12.81 | +17.10% | 1 | Mar 16, 2026 | |
| ABVX ABIVAX Société Anonyme | Initiates: Buy | $160 | $111.90 | +42.98% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $420 → $290 | $298.90 | -2.98% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $522 → $330 | $308.51 | +6.97% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $120 → $94 | $95.72 | -1.79% | 1 | Mar 16, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $13 → $16 | $14.27 | +12.12% | 2 | Nov 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $4 | $4.16 | -3.85% | 2 | Nov 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $29 → $40 | $28.55 | +40.11% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $20 | $13.00 | +53.85% | 1 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $1 | $0.79 | +26.44% | 2 | Sep 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $4 → $2 | $7.72 | -74.09% | 2 | Aug 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $88 → $102 | $85.20 | +19.72% | 2 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $3 → $1 | $4.04 | -75.25% | 2 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $71.90 | -37.41% | 1 | Apr 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $16 | $16.49 | -2.97% | 1 | Mar 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | $33 → $2 | $1.21 | +65.29% | 2 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $80 | $79.60 | +0.50% | 1 | Dec 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $15 | $5.41 | +177.26% | 1 | Nov 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $45 | $17.35 | +159.37% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $7 | $1.53 | +357.52% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $8 | $2.63 | +204.18% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Outperform | $50 | $9.98 | +401.00% | 1 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $11 | $2.30 | +377.85% | 1 | Mar 21, 2023 |
Syndax Pharmaceuticals
Mar 30, 2026
Assumes: Buy
Price Target: $48 → $40
Current: $21.00
Upside: +90.48%
4D Molecular Therapeutics
Mar 30, 2026
Assumes: Buy
Price Target: $40 → $21
Current: $9.45
Upside: +122.22%
PTC Therapeutics
Mar 30, 2026
Downgrades: Hold
Price Target: $91 → $76
Current: $69.22
Upside: +9.79%
Verastem
Mar 30, 2026
Assumes: Buy
Price Target: $19 → $15
Current: $5.54
Upside: +170.76%
Protagonist Therapeutics
Mar 19, 2026
Maintains: Outperform
Price Target: $107 → $110
Current: $98.51
Upside: +11.66%
Kymera Therapeutics
Mar 16, 2026
Assumes: Buy
Price Target: $122 → $110
Current: $86.68
Upside: +26.90%
Insmed
Mar 16, 2026
Assumes: Buy
Price Target: $228
Current: $135.98
Upside: +67.67%
Cogent Biosciences
Mar 16, 2026
Assumes: Buy
Price Target: $55
Current: $36.61
Upside: +50.25%
Design Therapeutics
Mar 16, 2026
Initiates: Buy
Price Target: $15
Current: $12.81
Upside: +17.10%
ABIVAX Société Anonyme
Mar 16, 2026
Initiates: Buy
Price Target: $160
Current: $111.90
Upside: +42.98%
Mar 16, 2026
Downgrades: Hold
Price Target: $420 → $290
Current: $298.90
Upside: -2.98%
Mar 16, 2026
Downgrades: Hold
Price Target: $522 → $330
Current: $308.51
Upside: +6.97%
Mar 16, 2026
Downgrades: Hold
Price Target: $120 → $94
Current: $95.72
Upside: -1.79%
Nov 20, 2025
Maintains: Outperform
Price Target: $13 → $16
Current: $14.27
Upside: +12.12%
Nov 7, 2025
Downgrades: Market Perform
Price Target: $4
Current: $4.16
Upside: -3.85%
Oct 21, 2025
Upgrades: Outperform
Price Target: $29 → $40
Current: $28.55
Upside: +40.11%
Sep 25, 2025
Initiates: Outperform
Price Target: $20
Current: $13.00
Upside: +53.85%
Sep 15, 2025
Downgrades: Market Perform
Price Target: $1
Current: $0.79
Upside: +26.44%
Aug 14, 2025
Maintains: Outperform
Price Target: $4 → $2
Current: $7.72
Upside: -74.09%
Jul 10, 2025
Maintains: Outperform
Price Target: $88 → $102
Current: $85.20
Upside: +19.72%
Apr 14, 2025
Maintains: Market Perform
Price Target: $3 → $1
Current: $4.04
Upside: -75.25%
Apr 8, 2025
Initiates: Outperform
Price Target: $45
Current: $71.90
Upside: -37.41%
Mar 17, 2025
Initiates: Market Perform
Price Target: $16
Current: $16.49
Upside: -2.97%
Mar 3, 2025
Downgrades: Market Perform
Price Target: $33 → $2
Current: $1.21
Upside: +65.29%
Dec 11, 2024
Initiates: Outperform
Price Target: $80
Current: $79.60
Upside: +0.50%
Nov 4, 2024
Initiates: Outperform
Price Target: $15
Current: $5.41
Upside: +177.26%
Sep 9, 2024
Assumes: Outperform
Price Target: $45
Current: $17.35
Upside: +159.37%
Sep 9, 2024
Initiates: Outperform
Price Target: $7
Current: $1.53
Upside: +357.52%
Sep 9, 2024
Assumes: Outperform
Price Target: $8
Current: $2.63
Upside: +204.18%
Sep 9, 2024
Assumes: Outperform
Price Target: $50
Current: $9.98
Upside: +401.00%
Mar 21, 2023
Initiates: Outperform
Price Target: $11
Current: $2.30
Upside: +377.85%